1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Molecule Holdings Inc.

Molecule Holdings Inc.

EVRRF
Molecule Holdings Inc.US flagOther OTC
0.00
USD
- -
- -
626,130.00Market Cap
2019 Y
2020 Y
2021 Y
2022 Y
TTM
Revenue per Share
- -
- -
- -
0.02
0.02
Basic EPS, GAAP
-0.02
-0.04
-0.05
-0.05
-0.04
Free Cash Flow per Basic Share
-0.06
-0.04
-0.03
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
0.09
0.04
- -
-0.05
-0.07
Tangible Book Value per Share
0.09
0.05
0.01
-0.04
-0.06
Basic Weighted Avg Shares
47
76
92
97
98
Sales/Revenue/Turnover
- -
- -
- -
2
2
Operating Margin (%)
- -
- -
-745.48
-198.86
-147.08
Depreciation Expense
- -
- -
1
1
1
Net Income, GAAP
-1
-3
-4
-5
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-928.56
-230.84
-200.5
Working Capital
2
- -
-2
-6
-8
LT Debt
- -
1
1
- -
- -
Total Equity
4
3
1
-4
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-94.03
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Jan'23
Apr'23
Jul'23
ST Debt
5
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
98
98
98
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Jan'23
Apr'23
Jul'23
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
1
- -
Total Current Liabilities
8
8
9
Payables & Accruals
3
3
3
ST Debt
5
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-678.77%
Free Cash Flow
- -
- -
-60.54%
Net Income, GAAP
- -
- -
7.49%
Sales/Revenue/Turnover
- -
- -
332.37%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
1
1
2
2023
- -
- -
1
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.01
-0.02
-0.01
- -
-0.05
2022
-0.01
-0.01
-0.01
- -
-0.05
2023
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David Reingold
Full Time Employees
13
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
591 Reynolds Road Lansdowne ON Canada K0E 1L0
IPO Date
Sep 22, 2020
Website
molecule.ca
Similar Companies
Pak Fah Yeow International Limited (0239.HK)
Bafna Pharmaceuticals Limited (BAFNAPHARM.BO)
TerrAscend Corp. (TSNDF)
North China Pharmaceutical Company Ltd. (600812.SS)
Jupiter Wellness, Inc. (JUPWW)
Windlas Biotech Limited (WINDLAS.NS)
Business
Molecule Holdings Inc. (CSE: MLCL, OTC: EVRRF) engages in the production and co-packing of cannabis-infused beverages and edibles in Canada; it provides infrastructure, know-how, technology, and licensing to craft producers for creating consumable cannabis products, including beverages, extracts, edibles, and topicals sold directly to provincial retailers. The company offers its branded products under the PHRESH, KLÕN, EMBODY, and CANAJO lines; it targets the adult-use and medical cannabis markets through partnerships with licensed producers and sales representatives. Founded in 2004 by André D. Audet, Brad Stewart, and Amy Proulx, Molecule Holdings is headquartered at 591 Reynolds Road in Lansdowne, Ontario, Canada, with operations focused domestically in the healthcare sector's drug manufacturers specialty and generic industry. In recent developments, the company completed amendment and conversion transactions of its 8% unsecured convertible debentures on November 28, 2024, and June 2, 2025, aimed at restructuring obligations and supporting ongoing operations amid regulatory challenges; it also secured a third partial revocation order from the Ontario Securities Commission on March 4, 2025, partially lifting a failure-to-file cease trade order to enable certain trading and filings. Earlier, Molecule entered a sales representation agreement with Humble+Cannabis Solutions Inc. in April 2022 to expand national distribution, while maintaining production capabilities following its CSE listing in September 2020 and a 1-for-10 stock split in October 2020; the firm continues to report quarterly earnings, with releases as recent as May 2025 showing modest revenues around $700,000 CAD.